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Abstract
An increasing number of broadly neutralizing monoclonal antibodies (bnMAb) against the HIV-1 envelope (Env) protein has
been discovered recently. Despite this progress, vaccination efforts with the aim to re-elicit bnMAbs that provide protective
immunity have failed so far. Herein, we describe the development of a mammalian cell based FACS-panning method in
which bnMAbs are used as tools to select surface-exposed envelope variants according to their binding affinity. For that
purpose, an HIV-1 derived lentiviral vector was developed to infect HEK293T cells at low multiplicity of infection (MOI) in
order to link Env phenotype and genotype. For proof of principle, a gp145 Env model-library was established in which the
complete V3 domain was substituted by five strain specific V3 loop sequences with known binding affinities to nMAb 447-
52D, respectively. Env genes were recovered from selected cells by PCR, subcloned into a lentiviral vector (i) to determine
and quantify the enrichment nMAb binders and (ii) to generate a new batch of transduction competent particles. After 2
selection cycles the Env variant with highest affinity was enriched 20-fold and represented 80% of the remaining Env
population. Exploiting the recently described bnMAbs, this procedure might prove useful in selecting Env proteins from
large Env libraries with the potential to elicit bnMAbs when used as vaccine candidates.
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Introduction
The HIV-1 envelope protein (Env) is translated as a 160 kDa
precursor glycoprotein. gp160 is cleaved by a furin protease into
an extracellular moiety gp120 and a transmembrane domain
gp41. These non-covalently associated heterodimers form trimeric
complexes exposed on the host cell membrane. Env is the only
viral protein that is exposed on both the host cellular and viral
membrane.
To date, almost all licensed vaccines against viral pathogens are
believed to protect by inducing pathogen specific antibodies.
Despite global efforts, the development of a vaccine that is capable
of mediating an antibody based protective immunity against HIV
has failed so far. During the past two decades, more than 30
candidate vaccines have been tested in human clinical trials [1,2].
These studies assessed replicating or replication-defective vectored
vaccines encoding selected HIV-1 antigens, HIV-1 DNA or RNA
vaccines as well as soluble HIV-1 proteins and peptide derivatives,
in various adjuvant formulations and prime/boost regimens [2–6].
To the extent, these efforts have been taken forward to phase IIB
or phase III efficacy trials, strategies that have successfully worked
for other pathogens have mostly failed to elicit protective
immunity towards HIV-1 infection. Cautious optimism was
created by the recently published results of the RV144 trial [3]
that revealed a,30% protection in those volunteers, who received
the vaccine. Notably, a non-neutralizing IgG antibody response
against V1/V2 and in particular IgG3 specific antibodies seem to
contribute to protection from infection [7].
Although it is widely agreed that an effective vaccine will need
to induce both B-cell and T-cell (CD4+ and CD8+) responses [6],
the exact mode needed for a protective, vaccine-induced immune
response against HIV-1 is still unclear. Conceptually, an early
neutralization of HIV-1 before an infection of target cells can
occur, e.g. during mucosal transmission seems highly attractive in
order to avoid integration of HIV-1 and formation of latently
infected reservoirs [8–10]. Passive immunization experiments
provided ample evidence that a vaccine, which is able to induce
bnMAbs in sufficient concentrations at the mucosal entry sites can
protect from infection [11,12].
Recently, several ‘‘reverse vaccinology’’ [13] approaches that
aimed at shifting the immune response [14] towards neutralization
relevant Env epitopes led to promising results [15,16]: Applying a
directed molecular evolution approach, Du et al. [17] identified
chimeric gp120 Env variants (ST-008), which elicited neutralizing
antibody responses in rabbits. Other approaches intended to shift
the immune response by heterologous substitutions or deletion of
the V1 loop, thus improving the immunogenicity of several
potentially beneficial epitopes [18]. Alternatively, targeted hyper-
glycosylation of variable loops [19] or chemical cross-linking [20],
are used for focussing antibody responses to desired epitopes such
as the CD4 binding site.
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Recent evidence raised hope that trimeric Env complexes may
have the potential to induce broadly neutralizing antibodies that
targets highly potent neutralizing structures e.g. quaternary
epitopes [17,21–25]. Screening technologies, which allow the
selection of trimeric Env out of a large library by bnMAb affinity-
enrichment may therefore lead to the identification of Env
complexes capable of re-eliciting antibody responses with broad-
ened neutralization profiles [11,15,26–28].
Recently, several broadly neutralizing monoclonal antibodies
(bnMAbs) have been discovered [1,2,11,29], accelerating the
antibody (B-cell) mediated vaccine strategies [2–6,30]. Therefore,
it has been hypothesized that particularly the presentation of
trimeric Env complexes as also found on the virus or cell
membrane may be necessary at least for the induction of some
highly potent bnMAbs e.g. PG16 [3,23,31]. Herein, describe the
development of a FACS-based, mammalian-cell display- and
panning- platform in order to screen for such potential HIV-1
candidate vaccines. For proof-of-principle, a chimeric Env/V3
model-library of few variants with known affinities to a V3-binding
antibody 447-52D [7,32–36] was successfully established and used
to demonstrate the intended enrichment of a membrane-bound




Herein, we describe the development of a mammalian-cell
based surface display and antibody driven FACS-screening
method that allows the identification of affinity enriched variants
of the HIV-1 envelope protein. The ultimate goal is to provide a
technology platform enabling the identification of HIV candidate
vaccines from comprehensive envelope libraries. In brief, the
procedure as developed comprises six steps, which are summarized
in Figure 1 and will be described in the following sections in more
detail.
HIV-1 chimeric Env/V3 model library and 447-52D model
antibody
As model antibody in the proof of concept study the neutralizing
monoclonal antibody (nMAb) 447-52D [6,32–34] was selected for
the following reasons: (i) 447-52D was available at the onset of the
study in sufficient amounts, (ii) distinct binding affinities to V3 loop
peptides representing 5 different virus strains (MN, RF, CDC42,
HXB2, SF33) were known [8–10,34], (iii) 447-52D has been
described as a neutralizing monoclonal antibody, shown to
neutralize mainly clade-B Tier 1 and some Tier 2 isolates,
targeting a linear (conformational influenced) epitope
[11,12,30,37]. For proof of principle, a gp145 Env model library
comprising the external glycoprotein gp120, the extracellular gp41
domain as well as the gp41 derived transmembrane domain was
established in which the complete V3 domain within a clade C
96ZM Env backbone was substituted by the above strain specific
V3 loop sequences, respectively. The resulting chimeras were
cloned into the lentiviral pQL vector system to generate the 96ZM
Env/V3 model library (Figure 2).
QL-cloning system with pQL plasmids
For convenient and highly efficient cloning of prospectively
larger Env libraries the design of lentiviral vector constructs was
optimized to enable a one-tube QL (Quick-Ligation) restriction-
ligation procedure modified from the ‘‘golden-gate’’ system
[13,38,39] (Figure 2 A).
With this system usually only very few (,0.01%) false positive
bacteria were obtained on control plates. Consequently, almost all
bacterial colonies, as probed by PCR, were successfully trans-
formed with an Env coding plasmid (.99,99%) as intended.
Expression of chimeric Env/V3 variants correlates with
reporter GFP expression
Expression of the chimeric Env variants within the Env/V3
library was genetically linked to GFP expression via an IRES site,
respectively (Figure 2 B). Equal expression of each chimeric Env/
V3 variant in relation to GFP was observed after staining of
transfected cells with an antibody (5F3), which was selected due to
its binding capabilities to a constant region shared by all chimeric
Env variants of the model library, respectively (Figure 3 A).
GFP and Env expression correlated positively (Pearson corre-
lation p,0.01) for all chimeric Env/V3 variants tested, respec-
tively, (Figure 3 B, Figure S3), thus nicely confirming translational
coupling the GFP marker and envelope expression.
Affinity analysis of 447-52D antibody binding to
individual members of the chimeric Env model library
As a prerequisite for calculating the affinity of antibody 447-
52D to each member of the chimeric Env/V3 library a time-
course was performed (Fig. 4A) and the impact of various antibody
dilutions were determined (Fig. 4B). For this purpose, equal
numbers of HEK293T cells were transduced separately, each at a
low MOI (0.1), respectively (Figure 4).
Incubation times longer than 10 min. did not lead to higher
MFI, respectively (Figure 4 A). An optimal antibody concentration
of 0.2 mg/mL was calculated to achieve the best discrimination
between the various chimeric Env variants (Figure 4 B/C). The
chimeric Env/V3 variant-MN showed highest affinity, followed by
variant-HXB2, -CDC42. Due to low signal intensity we were
unable to calculate Kd values for variant RF and SF33 (Figure 4
D). As a result, the demonstrated distribution of affinities was
considered feasible for the purpose of evaluating the following
panning procedure.
The FACS-panning strategy
In order to elaborate - defined conditions – for a feasible FACS
based gating strategy with optimal selection performance,
HEK293T (136106) cells were transduced at low MOI (0.1), 1st
by lentivirus particles derived from a plasmid mixture containing
equal amounts of all Env/V3 variants (Fig. 5A) and 2nd by
separately lentiviral particles each encoding only one of the
chimeric Env/V3-variants, respectively (Fig. 5B). Equal amounts
of transduced cells were harvested 72 h post transduction and
were analysed by FACS (Figure 5).
A typical sorting experiment is shown to illustrate the resulting
conditions for FACS-panning strategy. In order to select for living,
single cells a commonly used hierarchically gating strategy was
chosen (Figure 5 A). Cells infected with separate virus stocks of
each of the chimeric Env/V3-variants were applied to FACS-
sorting procedures utilizing a triangle shaped Gate (Gate 6,
Figure 5 B) for selection, respectively. Subsequently, data were
analyzed and a linear regression curve was calculated for each
variant. For clarity reasons, results are only shown for Env
variants-MN, -HXB2 and -SF33, representing a good (MN),
intermediate (HXB2) and weak (SF33) 447-52D binder (Figure 5
B). The distinct slopes of the regression curves demonstrate the
different ratio of 447-52D/GFP signals for each Env variant,
respectively. A higher ratio equals an higher affinity of 447-52D
towards the respective Env [14,40]. Therefore, stringency in
Mammalian Cell Based FACS-Panning for HIV-1 Vaccine Development
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selecting high affinity Envs was achieved by gating only the top
0.005% of all events (Figure 5 B, MN) [15,16,40,41]. The
distribution of cells reached with these parameters suggested that
only cells expressing Env variant-MN (10-counts) or -HXB2 (2-
counts) would be selected using the described FACS-sorting
protocol (Figure 5 B, Gate 6), leading to a stringent discrimination
of binder versus non-binder Env/V3-variants.
FACS-panning: Evaluation screen
In order to proceed from a defined mixture of separately
transduced cells to a more relevant setting of bulk infected cells,
different ratios of pQL9 based chimeric Env/V3-MN and -SF33
plasmids were first mixed and then used to produce corresponding
mixed virus batches. These batches were used to infect HEK293T
cells at low MOI of 0.1, respectively, thus representing two
member ‘‘minimal libraries’’ with different ratios of Env/V3-
variant MN (binding) and SF33 (non-binding) (Material and
Methods). Each of the subsequent panning cycle consists of six
steps (see Figure 1, Step 1–6), followed by quantitative enrichment
analyses after every cycle. The Env/V3-variant distributions were
analyzed using samples directly before each FACS-sorting
(Figure 1, Step 4/Figure 6, Input) and after the 1st and 2nd
complete cycle of panning (Figure 1, Step 5/Figure 6, 1st/2nd).
The ratios of the two chimeric Env/V3-variants were calculated
based on qPCR analysis (Figure 6 A-C) as well as DNA
sequencing of cloned envelope variants (Figure S4).
The results of these first panning experiments demonstrated the
ability of the FACS-panning and gating procedure to enrich a
‘‘binding’’ Env (MN) and deplete a ‘‘non-binding’’ Env (SF33). An
enrichment rate of ,3-fold for low Input values of MN (5% MN,
25% MN) (Figure 6 A, B) and an enrichment rate of ,10-fold for
high Input values of MN (50% MN) was achieved after 2 cycles of
selection (Figure 6 C; Table 1).
FACS-panning: Screen of complete chimeric Env/V3
model-library
The complete chimeric Env/V3 model-library was screened
using the same FACS-panning and gating procedure as described
for the evaluation screen above. Briefly, a batch of viruses was
produced using the complete chimeric Env/V3 model-library with
a plasmid mixture bearing 20% of each V3 variant. Subsequently,
fresh HEK293T cells were transduced with low MOI (0.1) and a
FACS-panning (Material and Methods) was performed (Figure 7
B).
Equal input values for each chimeric Env variant (,20%) has
been achieved (Figure 7 B; Input). As analyzed by qPCR a
continuously increase of the Env/V3-variant MN (19%, 31%,
58%) was achieved by FACS-panning and gating. Statistical
analysis of the panning revealed that the Env/V3-variant MN was
significantly enriched after the 2nd cycle of panning (Figure 7 B).
Selection of the highest-affinity binding chimeric Env/V3-variant-
MN out of an equally proportioned Env/V3 model-library
mixture was demonstrated.
FACS-panning: Improved screening efficacy
In order to further increase the enrichment efficacy a revised
plasmid, pQL11, was designed to improve the level of Env
Figure 1. Schematic overview of the FACS-panning procedure. HEK293T cells are transfected with a plasmid mix comprising (i) a lentiviral
vector plasmid (pQL9/11) encoding the Env/V3 model library, (ii) a packaging construct (pTNpack) as well as (iii) pVSV-G to render released particles
transduction competent (1). Linkage between geno- and phenotype from the initially ‘‘unlinked’’ virus library is achieved by low MOI infection of new
cells (2). Antibodies (e.g. bnMAb) are applied to bind cells expressing the various envelopes, respectively (3). Envelope expressing cells displaying the
highest MFI to the bnMAb and an internal control (GFP) are selected by a FACS-sorting procedure (4). Cells are collected and lysed prior to amplifying
the envelope genes from genomic DNA (5). The recovered envelope genes are cloned into pQL9/11 and analyzed by sequencing and realtime-PCR
(6). Fresh cells are transfected (together with pTN pack and pVSV-G) to produce new virus for Low MOI infection of fresh cells, thus entering a new
cycle of selection.
doi:10.1371/journal.pone.0109196.g001
Mammalian Cell Based FACS-Panning for HIV-1 Vaccine Development
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e109196
expression (Figure S5). This was achieved by substituting the IRES
with the TaVp2A peptide [17,42] (Figure 8 A). Hence, the
chimeric Env/V3 model library described above was subcloned
into the revised pQL11 plasmid.
Consequently, the complete pQL11 based Env/V3 model-
library was screened using the same FACS-panning and gating
procedure as described in the previous sections. Briefly, new
batches of viruses were produced using the complete chimeric
Env/V3 model-library with plasmid mixtures bearing 20% of each
chimeric V3 variant, respectively. Subsequently, fresh HEK293T
cells were infected at low MOI (0.1) and a FACS-panning
(Material and Methods) was performed. The distribution of Env/
V3-variants during two cycles of selection was monitored by qPCR
(Figure 8 B).
Equal Input values for each of the five chimeric Env/V3
variants (,20%) were achieved (Figure 8 B; Input). In comparison
to panning using pQL9 (Figure 7) a more efficient enrichment of
the Env/V3-variant MN (Input: 17% MN; 1st cycle: 55% MN; 2nd
cycle 81% MN) was achieved by using pQL11. Statistical analysis
of the panning revealed that the Env/V3-variant MN was highly
significantly enriched after the 2nd cycle of panning (P,0.001).
Thus, a more stringent selection of the highest-affinity binding
chimeric Env/V3-variant-MN out of an equally proportioned
Env/V3 model-library mixture was demonstrated.
The enrichment factors of all FACS-panning experiments in
relation to Input amounts are summarized in Table 1.
Whereas the utilization of pQL9 (Env-GFP coupling by IRES)
resulted in a ,6-fold enrichment of the Env/V3 variant MN, the
vector improvement leading to pQL11 (Env-GFP coupling by
TaVp2A) further improved the enrichment up to ,20-fold.
Taken together, these proof-of-concept experiments successfully
demonstrated the capability to specifically enrich the envelope
variant harboring the V3 MN domain, which has been shown to
bind with the highest affinity towards 447-52D nMAb, from a pool
of competing envelope V3 chimeras.
Discussion
Recent progress in the field of envelope specific B-cell isolation
and monoclonal antibody generation out of chronically infected
patients lead to a broad panel of available bnMAbs [11,18,43]. As
these antibodies can suppress established HIV-1 infection and can
protect from SHIV-1 challenge in animal models [19,44,45] they
are valuable tools for envelope based vaccine design. Several
groups pursue a targeted design of envelope immunogens based on
available structural information of the bnMAbs in complex with
the envelope protein especially the CD4 binding site [20,46,47].
Complementary, methods based on protein display and selection
could provide additional information of bnMAbs/envelope
interactions for vaccine design. Ideally, the method should mimic
the natural situation of an envelope protein regarding glycosyla-
tion, oligomerisation and surface presentation to allow proper
presentation of quaternary epitopes. Various available display
systems allow the screening of diverse proteins or peptides out of
comprehensive libraries to identify high affinity antigen-antibody
interactions, but most of them are not compatible with the
requirements [17,21–25,48–52]. The FACS-panning technology
developed by our group is based on the display of envelopes on the
HEK293T mammalian cell line, which is widely used e.g. as a
producer cell-line for functional Env pseudoviruses for HIV-1
neutralization assays [11,15,26–28,53,54]. It allows mammalian
Figure 2. Schematic overview of the QL cloning procedure. An envelope gene or an envelope library is amplified with primers to introduce
flanking Esp3I restriction sites enabling the generation of a 59 NcoI and a 39 Xho sitey (A; top). The envelope gene or an envelope library is incubated
together with pQL9/11 in a one-tube reaction with Esp3I and T4-Ligase. Compatible ‘‘sticky-ends’’ (equally colored) can be ligated successfully, direct
proper orientation and mediating resistance for further cleavage (A). Following transformation of CcdB sensitive bacteria, only recipients bearing a
plasmid without CcdB are able to form colonies in the presence of ampicillin. (B) The lentiviral vector construct pQL9 comprises (i) 59LTR (Long
terminal repeat), (ii) EF1a (human promotor), (iii) GFP (marker gene), (iv) an IRES (internal ribosome entry site), (v) a CcdB positive selection marker
[58], and (vi) a 39LTR sequence.
doi:10.1371/journal.pone.0109196.g002
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glycosylations, as well as a functional Env expression in membrane
context like in standardized neutralization assays. Therefore, it
should provide access to all of the proposed requirements of
envelope presentation, even to the promising quaternary structures
of Env [55] as mentioned above.
For the generation of cells expressing envelope variants we
chose a lentiviral vector system which allows efficient transduction
of various cell types and a stable transgene expression by
integration [56]. In contrast to transient transfections [37] were
multiple library variants are transfected into a single cell, a low
MOI transduction should promote a strong linkage between
phenotype and genotype [63,64,65]. To further improve our
panning strategy the vector was modified to allow a gfp based
normalization for differences in expression of the transgenes
(Fig.3). As other mammalian cell displays select directly for high-
level expression [63,64,65], we adjusted our FACS sorting
procedure to select for most efficient antibody binding relative to
gfp normalization (Fig.5). By the use of a more stringent coupling
of transgene and gfp on a translational level we could further
improve this selection method (Fig. S5).
As a proof-of-concept tool, a chimeric, 5-member Env/V3
model-library was created based on knowledge of earlier
experiments by Gorny et al. [34]. They determined the
dissociation constants (KD) of V3-peptides from different HIV-1
strains to the biochemically well-characterized nMAb 447-52D
[32–34]. While the generation of Env/V3-variants with diverging
affinity to 447-52D could be achieved using complete cell-surface
exposed envelopes, a different order of affinities between the V3
sequences with regard to 447-52D binding was observed,
underlining the importance of binding studies in the context of a
full length extracellular envelope.
Our FACS-panning and gating procedure could successfully
discriminate between the five chimeric envelope variants as
detected by two different methods: Sanger sequencing of selected
clones is an established and widely used method for the
determination of selected variants in display and selection methods
[53,65]. It represents however only a drawn sample out of all
selected variants and their significance is strongly dependent on
the size of variability in the input material. Therefore we
developed a qPCR enrichment-analysis based on total genomic
DNA isolated out of cells from the high binding population. As the
number of variants analyzed in this proof of concept study was
low, both methods detected the enrichment rate equally (Fig. S6).
By the use of the pQL11 vector we could detect an enrichment
rate of 20-fold after two rounds of selection. Other display
technologies reported higher enrichment rates, which were
however calculated only based on the selection between binders
versus non-binders using a mixture of cell populations [37,53].
Hence, the FACS-panning demonstrated herein, offers a unique
solution for bnMAb-dependent, affinity-enrichment of Env
proteins expressed on mammalian cell surfaces following trans-
duction with a swarm of lentiviral particles.
The identification and use of complete trimeric envelopes in an
active immunization scenario is considered very promising
regarding the elicitation of broadly neutralizing antibodies in
vaccinees [57]. It remains to be demonstrated in future studies to
which extent trimeric envelopes that were selected based on
improved antigenicity in terms of in vitro binding properties to one
or several of the available bnMAbs will be able to elicit a
polyclonal antibody response in vivo exhibiting a broadened
neutralization profile. As a necessary prerequisite, future screening
efforts analyzing more comprehensive Env libraries have to
demonstrate, to which extent it will be possible to isolate specific
Env conformations using e.g. potent bnMAb (e.g. VRC01 [58];
PG9/16 or PGT123 [11]). Additionally, it might be particularly
interesting to isolate a series of related Env vaccine candidates,
which bind to germline B-cell receptor (BCR), calculated
transition stages and the corresponding mature bnMAbs. The
consecutive vaccination with the accordingly selected envelope
variants might contribute towards guiding the formation of
germinal centers and eliciting broadly neutralizing antibody
responses [59–61].
In conclusion, we have herein provided proof-of-principle that
the mammalian cell-based display of complete HIV envelopes in
conjunction with a FACS procedure utilizing bnMAbs for panning
is capable of selecting high affinity binders from Env libraries.
Further studies will have to be directed towards further
challenging and possibly improving the described technology in
order to enable panning of high affinity binders from more
comprehensive envelope libraries. These will comprise at least
several hundreds of envelope variants from either genetically
engineered envelopes or libraries generated from PBMCs of
patients or vaccinees showing a certain breadth of neutralization.
Future studies will have to demonstrate to what extent envelopes
binding with increased affinity to the available bnMAbs and/or
their germline versions or intermediate precursors are capable of
inducing antibody responses with the desired breadth.
Materials and Methods
Construction of pQL9 and pQL11
The lentiviral plasmid pWPXLd (Addgene plasmid #12258)
[62] was used as a starting construct. Because of the presence of
Figure 3. Expression levels of chimeric Env/V3 and GFP.
HEK293T (36105) cells were separately transduced at MOI 1 by one of
the pQL9 derived transduction competent particles encoding one of
the chimeric Env/V3-variants, respectively. 72 h after transduction, cells
were harvested and stained with an APC-labeled 5F3 antibody binding
a constant region within the extracellular gp41 mojety and compared
to GFP mediated fluorescence (Pearson correlation p,0,01 for each
variant). A FACS analyses are depicted as the mean fluorescence
intensity (MFI) of APC labeled 5F3 antibody- and GFP-signals for all
chimeric Env/V3 variants, respectively. B The MFI ratios of 5F3 to GFP
signals were calculated, respectively.
doi:10.1371/journal.pone.0109196.g003
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Esp3I sites, the original backbone of pWPXLd was substituted by
non- Esp3I containing plasmid backbone part of pcDNA3.1(+) in
sequentially steps: (I) PCR amplification of the MCS (multiple
cloning site) of pcDNA3.1(+) and blunt-end ligation with pPCR-
Script-Amp linearized with EcoRV. (II) Subsequently, the plasmid
was linearized with EcoRV/XbaI within the MCS and ligated
with the lentiviral part of pWPXLd obtained by restriction with
SspI/XbaI (5.7 kb fragment). (III) The substitution of eGFP within
the WPXLd part by a CcdB (killer-gene [63]) expression cassette
flanked by two Esp3I restriction sites, cloned via MluI/NdeI.
Further on these plasmids were propagated in DB3.1 bacteria
(CcdB resistant). (IV) To further decrease the plasmid size, another
substitution of the plasmid backbone was performed by ligation of
the lentiviral part (EcoRI; blunt-ended; 5.4 kb) to a minimal part
of the pcDNA3.1(+) plasmid backbone (PciI/MfeI; blunt-ended;
dephosphorylated; 1.9 kb). (V) A GFP gene (GenBank # U55763)
was cloned into the MCS of pMACS LNGFR-IRES (#130-091-
887, Miltenyi Biotech) via EcoRI/BamHI. Subsequently, an
expression cassette consisting of GFP, synthetic Intron [64] and
an IRES site (internal ribosome entry site) (pQL9) or GFP,
TaVp2A [42] (pQL11) were introduced upstream of the CcdB
cloning site (via PCR amplification, extending the Insert with
MluI/NheI), resulting in the final pQL9 and pQL11 plasmids
respectively.
The QL cloning procedure
For cloning of DNA Inserts (envelopes) into pQL9 or pQL11 a
combined restriction and ligation process was used. The reaction is
divided into two steps. (I) 2 mL 10 x Tango Buffer (Fermentas),
2 mL 10 mM DTT, 100 ng pQL9/11, 100 ng Insert, 1 mL Esp3I
(Fermentas) and addition of H20 to reach 20 mL. This restriction
mixture containing the pQL plasmid vector and the DNA
fragment to be inserted (Insert) was incubated in a PCR cycler
for 45 min at 37uC. Meanwhile a second reaction for the ligation
was prepared. (II) 3 mL 10 mM ATP, 1 mL 10 x Tango Buffer,
1 mL 10 mM DTT, 1 mL T4-Ligase (NEB) addition of H20 to
reach 10 mL. Subsequently, the second was added to the first
reaction-mixture. The combined reactions were incubated in a
PCR cycler at 25uC, 37uC, 25uC for 45 min each. Finally, an
incubation step at 65uC for 10 min inactivates the enzymes in the
reaction mixture. A subsequent selection for positively cloned
plasmids is done by transformation of the CcdB sensitive bacterial
strain DH10B.
Construction of the chimeric Env/V3 model-library
A non-binding envelope of HIV-1 isolate 96ZM651 (Accession
number: AF286224) [65] was chosen as backbone for the
substitution of its complete V3 region with those of different
447-52D antibody binding HIV-1 isolates [34].
The DNA sequences comprising the complete V3 regions of
different HIV-1 isolates were adapted to human codon usage. The
plasmid pcDNA3.1-96ZMgp145 was used as template consisting
of a human codon adapted gp145 envelope coding region of
96ZM651 cloned into the MCS of pcDNA3.1(+). The V3 region
of the envelope 96ZM651 was substituted by fusion PCR, inserting
V3 regions of different isolates (see Table S1). Finally five different
96ZM651 based Env/V3-variants were chosen to form an Env/
V3 model-library of chimeric Envs that only differ in the small
region of V3. The constructs were cloned into the lentiviral pQL9
and pQL11 plasmid system by the QL cloning procedure. The
plasmids were validated by restriction and sequence analysis (data
not shown).
Figure 4. Affinity analysis of 447-52D antibody to individual members of the Env/V3 library. HEK293T cells were separately transduced at
low MOI (0.1) by one of the pQL9 derived lentiviral particles expressing the indicated chimeric Env/V3-variant, respectively. 48 h post transduction,
cells were stained with MAb 447-52D and an APC-labeled secondary antibody. The mean values of two independent experiments corrected for equal
GFP expression are shown. A A time-course with 447-52D antibody (10 mg/mL) was performed to record the incubation-time needed for equilibrium
binding. FACS data are expressed as the MFI for every member of the model library at the different incubation times, respectively. B 447-52D
antibody concentrations were serially diluted and incubated on infected cells at equilibrium incubation-time (1 h at 4uC) to obtain a concentration
dependent binding profile. C Cell populations stained with 0.1 mg/mL 447-52D antibodies are depicted separately in order to highlight the
differential binding at this concentration. D Dissociation constants (KD) were calculated from the antibody-titration curves shown in (B) based on the
mM concentrations derived from the 447-52D molecular weight and therefore expressed as Kd (mM). Data points were fitted by nonlinear least
squares regression (One site; Fit total and nonspecific binding, Graphpad Prism 5), and the resulting Kd as well as R
2 values are listed (#, non-
calculable).
doi:10.1371/journal.pone.0109196.g004
Mammalian Cell Based FACS-Panning for HIV-1 Vaccine Development
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e109196
Figure 5. FACS-panning: gating strategy. HEK293T (136106) cells were transduced at low MOI (0.1) (A) by lentivirus particles derived from a
plasmid mixture containing equal amounts of all Env/V3 variants and (B) by separately lentiviral particles each encoding only one of the chimeric Env/
V3-variants, respectively. Equal amounts of transduced cells were harvested 72 h post transduction and were analysed by FACS. A One typical sorting
experiment is shown to illustrate the FACS gating and sorting strategy: 50,000 events were recorded and a series of hierarchical gates were applied to
isolate single cells. GFP positive cells were gated within their main population (Gate 5) to exclude multiply infected cells (high GFP) and background
noise (low GFP). The GFP main population was subsequently gated for strong 447-52D antibody binding (high APC) in relation to Env expression
(coupled to the GFP signal). Therefore, a triangle shaped Gate (Gate 6) was chosen. The complete Gate hierarchy starting with all events is illustrated.
B Evaluation of the triangle-gate strategy: HEK293T cells (136106) were transduced at low MOI (0.1) with each pQL9 Env/V3-virus variant, respectively.
Cells were stained with 447-52D antibody and analyzed by FACS according to the gating strategy described in A. Cells that appeared in Gate 5 were
further analyzed by calculating a linear regression curve (purple). Slope values calculated for representative variants Env/V3-MN, Env/V3-HXB2, and
Env/V3-SF33 are indicated. The triangle shaped Gate 6 is shown in a log-scale dot plot. The numbers of events counted for Gate 5 and Gate 6 are
shown below each plot, respectively. Decreasing amounts of cells equal decreasing affinities of Env, as detected in the sorting Gate 6, ranging from
10 counts of Env/V3-MN, 2 of Env/V3-HXB2 and 0 of Env/V3-SF33, respectively.
doi:10.1371/journal.pone.0109196.g005
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Validating process for un-biased amplifications of the
chimeric Env/V3 model-library
Although all pQL Env/V3-plasmids share the same plasmid
and Env background, a bias in the selection of variants remained
possible. Such influences could bias the validity of results obtained
by the designed Env/V3 model-library. Especially, the influence of
a respective pQL Env/V3-library plasmid on bacterial growth
after transformation could lead to an unspecific bias in the
enrichment procedure and was therefore carefully analyzed. The
bacterial growth-rates and plasmid yields of separate over-night
cultures were analyzed by OD600 measurement, respectively. The
bacterial growth-rates were measured in five replicates. All strains
consistently had doubling-times of 7864 min. Subsequently,
isolated plasmid DNA were tested for correctly sized bands after
enzymatic restriction (AleI). All samples consistently showed
correctly sized restriction patterns, as well as equal plasmid
DNA yields (data not shown). Thus, a bias resulting from varying
bacterial plasmid propagation of the different Env/V3-variants
was excluded.
Furthermore, the accuracy of enrichment measurements is
dependent and therefore limited by the sample size analyzed.
Figure 6. FACS-panning using different ratios of Env/V3-variants MN and SF33. Different pQL9 Env/V3-variant plasmid mixtures containing
A 5% MN/95% SF33, B 25% MN/75% SF33, C 50% MN/50% SF33 were prepared. HEK293T cells (136106) were transfected (pQL9-mixture A, B or C
respectively, pTN pack, pVSV-G) to form an un-linked virus library. Fresh HEK293T cells (136106) were transduced at low MOI (0.1). The infected Env-
genotype-phenotype ‘‘linked’’ cells were applied to the above-described FACS-sorting procedure 48 h after infection. The envelope genes were
amplified from the genomic DNA of the collected cells, cloned into pQL9 and analyzed by qPCR. Fresh cells were transfected with the new pQL9 Env/
V3-mixture (together with pTN pack and pVSV-G) to produce new virus for low MOI transduction of fresh cells and to enter another cycle of selection.
The mean values of two independent experiments are shown. Statistics were calculated using the 1way-ANOVA followed by "Tukey’s Multiple
Comparison’’ test (* P,0.05; ** P,0.01; *** P,0.001). The relative amounts per variant of the input mixture, 1st and 2nd cycle are shown as analyzed
by qPCR (Efficiency‘-Ct as % of each variant; triplicates) [69–71]. A reference primer pair that amplifies a sequence independently of the Env gene
inserted was used to determine the total amount of pQL9 Env plasmids in each qPCR, respectively (data not shown).
doi:10.1371/journal.pone.0109196.g006
Mammalian Cell Based FACS-Panning for HIV-1 Vaccine Development
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e109196
Preliminary measurements were based on sequencing random
samples of single bacterial clones (Figure S4, S6), resulting in
enrichment rates accurate 610% within a confidence level of 95%
related to the parent population [66].
Further improvement in accuracy was achieved by establishing
a qPCR protocol allowing the specific detection of each Env/V3-
variant within a mixture of DNA (Figure S1), resulting in an
increase of statistical accuracy within a confidence level of 95%, up
to 60.05% [66].
Additionally, efficiencies of all primer pairs designed for qPCR
purposes as well as for the primer pairs that were used to amplify
complete Env genes were determined. Lastly, an equal efficiency
Table 1. Enrichment of Env/V3-variant MN.a
The specific enrichment of the Env/V3-variant MN is calculated for each FACS-panning.
Panning Ratio
a of Env recovered after 2 cycles (%)/Env Input (%) Fold enrichmentb
MN Non-MN
pQL9
Library Screen (Figure 7 B) 3.09 0.51 6.01
pQL11
Library Screen (Figure 8 B) 4.68 0.23 20.51
aValues obtained by qPCR.







# cycle of panning.
doi:10.1371/journal.pone.0109196.t001
Figure 7. FACS-panning with pQL9 based Env/V3- model library. A Schematic overview of pQL9 plasmid B HEK293T cells were transduced at
low MOI (0,1) of ‘‘linked’’ pQL9 derived chimeric Env/V3-model-library viruses and subjected to a FACS panning and gating procedure 48 h after
transduction (as described in Material and Methods and Figure 1/5). Env genes were amplified from genomic DNA of collected cells, cloned into fresh
pQL9 and were analyzed by qPCR. New virus batches were produced with the resulting new pQL9 Env-library mixtures for infections of fresh cells,
thus entering another cycle of selection. The mean values of four independent experiments are shown. Statistics were calculated using the 1-way-
ANOVA- (testing, whether mean values differ) and ‘‘Dunnett’s’’ post-test (testing, which mean values differ: * P,0.05; ** P,0.01; *** P,0.001). The
relative amounts per variant of the input mixture, 1st and 2nd cycle are shown as analyzed by qPCR (Efficiency‘-Ct as % of each variant). The total
amount of pQL9 Env/V3-plasmids in every sample was tested by a reference primer pair that amplifies a sequence independent of the Env genes,
respectively (data not shown).
doi:10.1371/journal.pone.0109196.g007
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of all primer pairs was observed (Figure S1). Taken together, no
bias was detected that could have shifted the enrichment results
additionally to the FACS-sorting procedure.
Transfection of HEK293T cells
Transfection of HEK293T cells was done according to common
transfection protocols [67]. Briefly, HEK293T cells were seeded to
reach 80% confluence on the day of transfection. As an example,
56105 cells were seeded in 2 mL DMEM (#41966, Invitrogen)
supplemented with 10% FCS (10270-106, GIBCO), 1% Pen/
Strep (P06-07100, PAN Biotech) medium into a 6-well plate the
day before transfection. Directly before transfection, the medium
was replaced by 1 mL of DMEM without supplements and
incubated as before until transfection. A transfection mixture was
prepared by diluting 2 mg of DNA into 100 mL DMEM without
supplements, adding 8 mL PEI (Polyethylenimine in sterile water
at 1 mg/mL) and incubation of 10 min at RT after vigorously
mixing on a vortex instrument. The prepared mixture was
pipetted to the cells by lifting the plate on one side and releasing
the mixture directly below the surface of the medium, mixed by
swirling and incubated for 6 h before the medium was replaced by
2 mL DMEM. After 24 to 72 h the cells or the supernatant were
harvested. If smaller or greater vessels were used, the amount of
cells, DNA, PEI and the amount of medium were scaled in
relation to the surface of the vessel.
Production of virus batches
Transfection of a three-component plasmid mixture of pTN-
pack/pQL9 or pQL11 based plasmids/pVSV-G (see Table S2)
into HEK293T cells initiated the production of viruses. The
plasmids were mixed in the ratio 4:3:1, with the total amount of
30 mg DNA. HEK293T cells were transfected in a 15 cm dish
according to the previously described protocol for the transfection
of HEK293T cells. After 72 h of incubation the supernatant was
cleared by centrifugation at 4uC, 30006g for 15 min, aliquots
were stored at 280uC or transferred onto a 30% sucrose cushion
by pipetting the sucrose solution carefully below the supernatant.
After ultracentrifugation (BD, Optima L90K) at 4uC, 1000006g
for 2 h the pellet was re-suspended in 300 mL of DMEM medium
over night at 4uC and stored in 50 mL portions at 280uC.
Infection and determination of multiplicity of infection
(MOI)
The day before infection 136106 cells in 30 mL DMEM (10%
FCS, 1% Pen/Strep) were seeded into a 15 cm dish, or 2.56104
cells in 0.5 mL into each well of a 6-well plate. Directly before
Figure 8. FACS-panning with improved pQL11 based Env/V3 model-library. A Schematic overview of the new pQL11 plasmid B HEK293T
cells were infected at low MOI (0,1) of ‘‘linked’’ pQL11 based chimeric Env/V3-model-library viruses and were applied to a FACS-panning procedure
48 h after infection (as described in Material and Methods and Figure 1/5). Env genes were amplified from genomic DNA of collected cells, cloned
into fresh pQL11 and were analyzed by qPCR. New virus batches were produced with the resulting new pQL11 Env-library mixtures for infections of
fresh cells, thus entering another cycle of selection. The mean values of three independent experiments are shown. Statistics were calculated using
the 1-way-ANOVA- (testing, whether mean values differ) and ‘‘Dunnett’s’’ post-test (testing, which mean values differ: * P,0.05; ** P,0.01; *** P,
0.001). The relative amounts per variant of the input mixture, 1st and 2nd cycle are shown as analyzed by qPCR (Efficiency‘-Ct as % of each variant). The
total amounts of pQL11 Env/V3-plasmids in every sample was tested by a reference primer pair that amplifies a sequence independent of the Env
genes, respectively (data not shown).
doi:10.1371/journal.pone.0109196.g008
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infection the medium was replaced by freshly prepared 20 mL, or
0.5 mL, DMEM containing 10 mg/mL Polybrene (10 mg/mL
Hexadimethrine bromide in sterile water, #H9268, Sigma). Virus
was thawed slowly on ice or was used directly after production.
Various amounts of virus were pipetted to the cells depending on
the experiment by lifting the dish or plate on one side and
releasing the virus directly below the surface of the medium, mixed
by swirling and incubated for 24 h before the medium was
replaced by 30 mL or 0.5 mL fresh DMEM medium. The cells
were assayed 48 h after infection. In order to determine the
amounts needed to achieve low MOI (#0.2) infections, the
infectivity of each virus production was deduced by infecting cells
with different amounts of virus. GFP positive cells were counted
after 48 h post infection by FACS analysis and related to the
volume of virus applied. The MOI was estimated to be in a range
of highest probability for singly infected cells (low MOI: #0.2) by
correlating the measured infection rate (% positive cells) and the
expected MOI according to the Poisson distribution (Figure S2).
Briefly, at MOI 0.2 the probability (P(n)) that a cell is infected by 0
(n) virus is 81.87% (the negative cells). All other cells are infected
by 1 (n) virus 16.37%, 2 (n) viruses 1.64% and so on. Therefore,
most cells getting infected at MOI #0.2 are singly infected cells.
FACS-analysis
Cells were detached with PBE (PBS +0.5% FCS, 2 mM EDTA,
1 mg/mL NaN3) and centrifuged at 2006g for 5 min at 4uC.
Subsequently, cells were incubated with 0.001–10 mg/mL 447-
52D antibody (AB014, Polymun) diluted in PBE at 4uC. Adjacent
incubation, cells were washed 3 x with 1 mL ice cold PBE,
centrifuged at 2006g for 5 min at 4uC. A secondary antibody anti-
human-IgG-APC (#109-136-098, Jackson) diluted in PBE was
applied for 1 h at 4uC. Another 3 x with 1 mL ice cold PBE
washing step followed and cells were centrifuged at 2006g for
5 min at 4uC. Finally, cells were suspended in PBE and subjected
to cytometric analysis. Un-transfected cells were treated equally
and used as background control. Env coupled GFP expression
signals (MFI) were used to calculate normalized Env expression
signals (MFI) when the affinity of 447-52D antibody was
determined or were used for gating desired cell populations in
the FACS-panning procedure. Cell preparations for cytometric
analysis were probed, using FACS Canto II or FACS Aria (Becton
Dickinson).
FACS-panning: Affinity enrichment and isolation of Env/
V3-variants
Cells were prepared according to the protocol described in the
previous section and were finally re-suspended in 1 mL PBE per
one 15 cm dish and filtered with a 30 mm pre-separation filter
(#130-041-407, Miltenyi Biotech). Cells were subjected to
cytometric sorting utilizing a FACS Aria instrument. The
instrument was set to ‘‘single cell mode’’ to obtain the most
accurate counts for the sorting procedure. In this mode drops
containing two target events are discarded. When a particle is
detected matching the criteria for separation, an electrical charge
is applied just as the droplet containing this particle breaks off from
the liquid stream. As the charged droplet passes strongly charged
deflection plates, it can be separated and collected [68]. The
genomic DNA of the sorted cells and a portion of cells before
sorting were prepared according to the manufacturer’s instructions
(#51104, Qiagen) but without addition of carrier DNA and
limited to 20 mL 10 mM Tris-elution buffer for increasing the
DNA concentration. To amplify viral integrated envelope genes
the genomic DNA was used as a template for Nested-PCR
reactions (Primer, see Table S1).
Quantitative PCR (qPCR)
In order to determine the efficiency of PCR reactions, a qPCR
standard curve analysis utilizing a StepOnePlus (Applied Biosys-
tems) device was performed. Genomic or plasmid sample DNA
was prepared and a 5-fold dilution series was analyzed according
to the manufacturer’s instructions (Applied Biosystems, as well as
Finnzymes). To determine the amount of different envelope
coding genes in a mixture of DNA, a qPCR reaction containing
one specific reverse-primer was designed for each gene analyzed.
Consequently, the probe and forward-primer was designed to bind
at a region with equal sequences for all different Env/V3-variants.
Furthermore, one additionally reverse-primer was designed that
binds at a region with equal sequences for all variants and
therefore was used as a reference primer, determining the total
amounts of the applied variants (Table S1, Figure S1). The
amount of the sample DNA used varies according to the
experimental setting. For both, SYBR Green chemistry and
probe-based chemistry, the manufacture’s reaction protocols were
used (DyNAmo F-415, F-455, Finnzymes).
Supporting Information
Figure S1 Verification of qPCR analyses. A Schematic
overview of qPCR components used. Consensus sequences are
color-coded. Sequences corresponding to Env are shown in black
and those for pQL plasmids are depicted in grey. Oligonucleotides
like primers or probes are shown as grey, black or colored arrows.
The colors and orientation visually connect the plasmid sequence
to its oligonucleotide binding area. The Probe is 59 labeled with
FAM and 39 quenched by BHQ1. B PCR efficiencies for all
primer pairs used on the V3 plasmids were calculated in order to
demonstrate comparable efficiencies between the different V3
constructs. Efficiencies for primer 8H1 and 8H2 were tested with
SYBR Green (mean and SD of two separate experiments). The
other primers were tested with probe-based qPCR. C Probe based
qPCR amplifications on plasmid mixtures were done to verify the
specificity of every possible combination of the Env V3-variants
used. The name of the colored samples indicates whether the
tested variant is present or absent. Triplicates of 5 mL of every
sample mixture (1 ng/mL) were tested with its corresponding
specific Primer-r, but with equal Primer-f and Probe. Rn values
(normalized Reporter) are the ratio of the fluorescence emission
intensity of the reporter (Probe) to the fluorescence emission
intensity of the passive reference dye (i.e. ROX). Rn is plotted
against the PCR cycle number to illustrate the amplification of
PCR products.
(TIF)
Figure S2 The Poisson distribution is used to calculate
the probability for cells to get infected with a specific
number of viruses at a given MOI. At low MOI (0.1–0.5) the
average fraction of cells that will become infected (P(n.0) = 1–
P(n = 0)) is approximately equal to the MOI (m). Furthermore, low
MOI infections lead predominantly to non- or single infection
events. This is especially true for the applied MOI of 0.1 (green),
but also remains true until the MOI of 0.5, as illustrated.
(TIF)
Figure S3 Ratio of 447-52D (APC) and GFP signals for
infected cells. HEK293T cells (36105) were infected with pQL9
Env V3-MN virus with the MOI indicated (MOI: 0.05–0.5) and
stained with 50 mL 447-52D antibody (10 mg/mL) 48 h after
infection. FACS analysis is shown for the different MOI of the
applied virus as the MFI of gated living cells. The ratio of 447-
52D/GFP is shown with a secondary axis to indicate the
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connection between the expression levels of the envelope variant
MN and GFP. The mean values of two independent experiments
are shown.
(TIF)
Figure S4 FACS-panning using different ratios of Env
V3-variants MN and SF33. The Panning procedure was
performed as described in Figure 6 A-C. Additionally to the
performed qPCR analysis (Figure 6) the relative amounts per
variant of the input-mixture, 1st and 2nd round were analyzed by
sequencing one 96-well plate of single clones each. The mean
values of two independent panning experiments are shown.
Statistics were calculated using the 1way-ANOVA followed by
"Tukey’s Multiple Comparison’’ test (* P,0.05; ** P,0.01; ***
P,0.001).
(TIF)
Figure S5 Improved linkage of coexpression. Represen-
tative samples of A pQL9-MN and B pQL11-MN low MOI
infected HEK293T cells were analyzed. A scatter plot of all 447-
52D antibody and GFP positive cells is shown. Linkage of
coexpression were further analyzed by calculating a linear
regression curve (purple) and R2 values respectively. The higher
R2 value depicted in B indicates a stronger linear approximation
for pQL11 based coexpression of envelope and GFP, than for
pQL9.
(TIF)
Figure S6 FACS-panning by sequencing single clones.
The Panning procedure was performed as described for Figure 7.
Additionally to the performed qPCR analysis the distribution of
variants were analyzed by sequencing one 96-well plate of single
clones for Input samples and after each cycle. The mean values of
four independent experiments are shown. Statistics were calculat-
ed using the 1-way-ANOVA- (testing, whether mean values differ)
and ‘‘Dunnett’s’’ post-test (testing, which mean values differ: * P,
0.05; ** P,0.01; *** P,0.001).
(TIF)
Table S1 Oligonucleotides. A complete list of all oligonucleo-
tides that were used for this project.
(DOC)
Table S2 Plasmid constructs. A complete list of all plasmids that
were used for this project.
(DOC)
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